Related Experiment Video
Updated: May 18, 2026
08:46
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
Published on: March 7, 2017
Genetics and pharmacogenomics of diffuse gliomas
H F van Thuijl1, B Ylstra, T Würdinger
1Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands.
Pharmacology & Therapeutics
|September 19, 2012
Summary
Pharmacogenomics offers personalized cancer therapy through molecular markers. Further research in diffuse gliomas is needed to unlock its full potential for improved patient outcomes.
Area of Science:
- Genomic analysis and cancer therapeutics.
- Pharmacogenomics and personalized medicine.
Background:
- Genome analysis techniques are rapidly advancing, creating new avenues for cancer treatment.
- Molecular markers are crucial for personalized therapy in diffuse gliomas, with established applications in other cancers like melanoma and lung carcinoma.
- Pharmacogenomics, the study of drug effects based on genetic makeup, shows promise but also limitations for diffuse gliomas.
Purpose of the Study:
- To explore the promise and limitations of pharmacogenomics in diffuse gliomas.
- To highlight the need for enhanced molecular characterization of diffuse gliomas.
- To underscore the importance of analyzing molecular underpinnings of drug efficacy in clinical trials.
Main Methods:
- Review of current genomic analysis techniques.
- Analysis of molecular markers in various cancer types.
- Examination of pharmacogenomic applications in clinical trials.
Main Results:
- Established molecular markers are used in melanoma, lung, breast, gastric, and colorectal cancers.
- Pharmacogenomic drugs are under investigation in clinical trials for various cancers.
- Diffuse gliomas require better molecular characterization to guide personalized therapy.
Conclusions:
- Pharmacogenomics holds significant promise for personalized diffuse glioma therapy.
- Further research into molecular characteristics and drug efficacy is essential.
- Anticipated advancements in the coming years are expected to benefit patients.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...